Relay Medical Corp.: Relay Medical and Glow LifeTech Report on Successful Phase II Clinical Results For COVID-19 Treatment Candidate Based On Its MyCell Technology
(2) Glow LifeTech has the exclusive rights for MyCell Technology in the United States, Canada and Mexico for one of the primary ingredients used in ArtemiC, a COVID-19 Treatment Candidate with successful Phase II Clinical Results The formulation statistically significantly improved the clinical recovery of COVID-19 patients in the treatment group in comparison with placebo and 100% of the patients in the treatment group fully recovered within 15 days Positive results from a phase II double blin...
Source: finanznachrichten.de